Biofrontera AG
OTC: BFFTF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Pilar de la Huerta Martinez
- Employees
- 97
- Headquarters
- Leverkusen, Germany
- IPO year
- 2018
- Market cap
- $19.3M
- Website
- https://www.biofrontera.com
Loading BFFTF…
Loading profile data…Frequently asked questions about BFFTF
What does Biofrontera AG (BFFTF) do?
Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threa...
Where does BFFTF trade?
Biofrontera AG (BFFTF) trades on the Other OTC.
What sector is BFFTF in?
Biofrontera AG (BFFTF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Biofrontera AG?
Pilar de la Huerta Martinez is the chief executive officer of Biofrontera AG (BFFTF).
Where is Biofrontera AG headquartered?
Biofrontera AG is headquartered in Germany.
Does BFFTF pay a dividend?
Biofrontera AG (BFFTF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BFFTF go public?
Biofrontera AG (BFFTF) completed its initial public offering in 2018.